SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The company witnessed a 9.89% growth in the revenue at Rs. 8110.00 millions for the quarter ended June 2024 as compared to Rs. 7380.20 millions during the year-ago period.Net Profit recorded in the quarter ended June 2024 rise to 39.11% to Rs. 1816.50  millions  compared to R. 1305.80 millions in corresponding previous quarter.The company reported a good operating profit of 2652.70 millions compared to 1780.50 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 8110.00 7380.20 9.89 8110.00 7380.20 9.89 34072.50 32163.40 5.94
Other Income 358.50 368.00 -2.58 358.50 368.00 -2.58 1234.80 1015.20 21.63
PBIDT 2652.70 1780.50 48.99 2652.70 1780.50 48.99 10241.30 9009.30 13.67
Interest 3.70 2.80 32.14 3.70 2.80 32.14 18.00 18.10 -0.55
PBDT 2649.00 1950.70 35.80 2649.00 1950.70 35.80 8787.20 8981.50 -2.16
Depreciation 164.10 163.60 0.31 164.10 163.60 0.31 696.80 657.70 5.94
PBT 2484.90 1787.10 39.05 2484.90 1787.10 39.05 8090.40 8323.80 -2.80
TAX 668.40 481.30 38.87 668.40 481.30 38.87 2243.50 2276.80 -1.46
Deferred Tax 35.10 -45.00 -178.00 35.10 -45.00 -178.00 -113.60 -183.70 -38.16
PAT 1816.50 1305.80 39.11 1816.50 1305.80 39.11 5846.90 6047.00 -3.31
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 32.71 24.13 35.58 32.71 24.13 35.58 30.06 28.01 7.31

Glaxosmithkline Phar Share Price

2406.25 -3.60 (-0.15%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×